August 11, 2009
A large effectiveness study comparing Schering-Plough's pegylated-interferon Pegintron and ribavirin with Roche's Pegasys and ribavirin shows both hepatitis C treatments worked equally well.
The study by Dr. Mark Sulkowski of Johns Hopkins University involved 3,000 patients with hepatitis C. Its findings are meant to help guide doctors' decisions about which treatments work best.
"There has been a lot of debate about these two regimens," said Dr. Andrew Muir of Duke University, a co-author of the Schering-Plough-funded study. "It's great to have a study of this size that really answers this question."
07.22.2009; Julie Steenhuysen
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|What's Hot in HIV Cure Research?|
|Extensively Drug-Resistant HIV Yields to a New Drug: Ibalizumab|
|A Review of Long-Acting HIV Treatment and Prevention|
|Top Menu Items From the Boiling Cauldron of HIV Clinical Research|
|This Week in HIV Research: Researchers Exonerate Long-Alleged 'Patient Zero,' and Triggering bNAb Production Shows Promise|